PAVmed shares fell 3.7% following the earnings release, reflecting investor disappointment with continued delays in key commercial milestones and a cautious near-term outlook despite ongoing pipeline progress.

• The company completed a capital structure cleanup, positioning for future growth, but no near-term revenue inflection was evident.
• Lucid Diagnostics remains a major focus, with Medicare coverage still delayed, maintaining uncertainty around significant revenue catalysts.
• Initial traction with the Veterans Administration and positive payer coverage offer some upside but have yet to drive meaningful volume or cash flow.
• Veris is progressing through clinical rollout and product development but remains in early commercialization with ongoing R&D spending on implantable devices and AI projects.
• Management discussed strategic expansion and potential business development opportunities but offered no updated guidance or specific timelines to ease investor concerns.